RxDoctor Payments Data

Kristen Michael, DO

Family Medicine · Bessemer, ALNPI 1982970232

Payments from drug & device makers

$16,027in general payments, 2019–2025

Across 1,027 payments — averaging $15.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$2K
  • AstraZeneca$2K
  • GSK$1K
  • Boehringer Ingelheim$976
  • Takeda Pharmaceuticals U.S.A., Inc.$898
  • plus $7K from 43 others

What the payments were for

  • Food & beverage$15,93899%
  • Education$891%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$16,027 in reported general payments places this provider in the 95th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$19,576
Medicare patients
87
Services billed
276

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide80$102,247
MounjaroTirzepatide79$93,551
OzempicSemaglutide75$82,286
JardianceEmpagliflozin72$80,456
Trelegy ElliptaFluticasone/Umeclidin/Vilanter96$80,155
EliquisApixaban73$65,637
LinzessLinaclotide44$50,497
FarxigaDapagliflozin Propanediol58$48,795
Synjardy XrEmpagliflozin/Metformin Hcl19$40,453
GemtesaVibegron56$36,553
VraylarCariprazine Hcl24$33,446
Breztri AerosphereBudesonide/Glycopyr/Formoterol32$21,406
Tresiba Flextouch U-200Insulin Degludec28$20,132
MyrbetriqMirabegron27$18,330
Tresiba Flextouch U-100Insulin Degludec34$18,255

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$829$195,799159 claims
Boehringer IngelheimJardiance, Synjardy Xr, Spiriva Respimat$976$128,129102 claims
AbbVieLinzess, Vraylar$1,914$83,94268 claims
Novo NordiskOzempic$2,461$82,28675 claims
GSKTrelegy Ellipta$1,007$80,15596 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,756$76,466114 claims
PfizerEliquis$492$65,63773 claims
Sumitomo Pharma America, Inc.Gemtesa$93$36,55356 claims
Astellas Pharma US IncMyrbetriq$75$18,33027 claims
Takeda Pharmaceuticals U.S.A., Inc.Dexilant$898$3,59712 claims
Shire North American Group IncMydayis$16$3,48711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Bessemer

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →